Current Status of PSMA-Targeted Agents Based on Small Molecules for Prostate Cancer in Preclinical Studies
{{output}}
Prostate-specific membrane antigen (PSMA) has emerged as a clinically validated target for the diagnosis and treatment of prostate cancer using radioligand therapy (RLT). Among various PSMA-targeting ligands, urea-based small-molecules have gained limelight du... ...
